Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 45 pages report, published by Global Markets Direct

Keywords : Herpes Labialis (Oral Herpes) Therapeutic Products under Development, Key Players in Herpes Labialis (Oral Herpes) Therapeutics, Herpes Labialis (Oral Herpes) Pipeline Overview, Herpes Labialis (Oral Herpes) Pipeline, Herpes Labialis (Oral Herpes) Pipeline Assessment

Report ThumbnailSeptember-2013
Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes). Herpes Labialis (Oral Herpes) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Herpes Labialis (Oral Herpes).
- A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Herpes Labialis (Oral Herpes) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2013 7
  • Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Herpes Labialis (Oral Herpes), H2 2013 7
  • Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • NanoViricides, Inc., H2 2013 14
  • BioAlliance Pharma SA, H2 2013 15
  • Foamix Ltd., H2 2013 16
  • NanoBio Corporation, H2 2013 17
  • Redox Pharmaceutical Corporation, H2 2013 18
  • Beech Tree Labs, Inc., H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Herpes Labialis (Oral Herpes) Therapeutics - Drug Profile Updates 34
  • Herpes Labialis (Oral Herpes) Therapeutics - Dormant Products 37
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Herpes Labialis (Oral Herpes) Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Herpes Labialis (Oral Herpes) 7
  • Herpes Labialis (Oral Herpes) Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Herpes Labialis (Oral Herpes) Therapeutics - Products under Development by Companies 13
  • Companies Involved in Herpes Labialis (Oral Herpes) Therapeutics Development 14
  • NanoViricides, Inc. 14
  • BioAlliance Pharma SA 15
  • Foamix Ltd. 16
  • NanoBio Corporation 17
  • Redox Pharmaceutical Corporation 18
  • Beech Tree Labs, Inc. 19
  • Herpes Labialis (Oral Herpes) - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • acyclovir - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • CTC-96 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • NB-001 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • BTL-TML-HSV - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • HerpeCide-I - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • ZEP-3 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • acyclovir - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Herpes Labialis (Oral Herpes) Therapeutics - Drug Profile Updates 34
  • Herpes Labialis (Oral Herpes) Therapeutics - Dormant Products 37
  • Herpes Labialis (Oral Herpes) - Product Development Milestones 38
  • Featured News & Press Releases 38
  • Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 38
  • May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 38
  • Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 39
  • Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 40
  • Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 40
  • May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 41
  • Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 41
  • May 11, 2011: NanoBio And GSK Commence Phase III Studies Of Nanoemulsion-based OTC Treatment For Cold Sores 42
  • Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 42
  • Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 43
  • Appendix 44
  • Methodology 44
  • Coverage 44
  • Secondary Research 44
  • Primary Research 44
  • Expert Panel Validation 44
  • Contact Us 45
  • Disclaimer 45

Please select a license type

Share

Related Products

Global Markets DirectHerpes Labialis (Oral Herpes) - Pipeline Review, H2 2013Product ThumbnailHerpes Labialis (Oral Herpes) - Pipeline Review, H2 2013, Industry ReportProduct #: 113339
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved